China Shenghuo Pharmaceutical Holdings, a China-based pharmaceutical company primarily engaged in the research, development and manufacture of traditional Chinese medicine (TCM), has hired Raymond Wang as part-time chief financial officer (CFO). He joins from China Biwin Consulting and Guangzhou Biwin Financial Consulting, where he was responsible for financial consulting, internal controls, tax and Sarbanes-Oxley (SOX) Section 404 compliance.
Wang began his career at one of Big Four accounting firms where he managed audit engagements, reviewed the working papers, communicated with top management and liaised with internal tax professionals. He later worked at another US accounting firm, where his responsibilities included US generally accepted accounting practices (GAAP) audits, advisory service on the compliance with SOX 404 and pre-audit advisory service, such as enhancing the internal control, preparing financial reports and US GAAP conversion. He holds a Bachelor of Business degree from Guangdong University of Foreign Studies and is a member of the Chinese Institute of Certified Public Accountants (CICPA). He is fluent in English, Mandarin and Cantonese.
The former CFO, Chuanxiang Huang, has resigned from his position as CFO, effective 18 April 2011.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.